PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Completed
Pfizer
Phase 2
2010-09-23
The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance)
(formerly known as PD0332991) has on the patient and on the liposarcoma.
Palbociclib is an investigational drug. An investigational drug is a medication that has not
been approved for marketing by the Food and Drug Administration (FDA). Palbociclib blocks a
protein called CDK4 which is part of a pathway in liposarcoma cells that is over-active. The
investigators hope that blocking CDK4 will shut down this pathway in the liposarcoma cells
and stop tumors from growing. Palbociclib is an oral medication.
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Completed
Memorial Sloan Kettering Cancer Center
Phase 2
2010-09-23
The purpose of this study is to find out what effects, good and/or bad, Palbociclib (Ibrance)
(formerly known as PD0332991) has on the patient and on the liposarcoma.
Palbociclib is an investigational drug. An investigational drug is a medication that has not
been approved for marketing by the Food and Drug Administration (FDA). Palbociclib blocks a
protein called CDK4 which is part of a pathway in liposarcoma cells that is over-active. The
investigators hope that blocking CDK4 will shut down this pathway in the liposarcoma cells
and stop tumors from growing. Palbociclib is an oral medication.
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Active, not recruiting
AGO Study Group
Phase 3
2013-11-01
The PENELOPEB study is designed to demonstrate that in the background of standard
anti-hormonal therapy palbociclib provides superior invasive disease-free survival (iDFS)
compared to placebo in pre- and postmenopausal women with HR-positive/HER2-normal early
breast cancer at high risk of relapse after showing less than pathological complete response
to neoadjuvant taxane- containing chemotherapy. Considering the high risk of recurrence in
patients after neoadjuvant chemotherapy and a high CPS-EG score, palbociclib appears to be an
attractive option with a favourable safety profile for these patients.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
